News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 12 - 05

Zero2IPO's 25th China Equity Investment Annual Conference Grandly Opens in Shenzhen

From December 2 to 5, 2025, the 25th China Equity Investment Annual Conference, hosted by Zero2IPO Holdings and Pedata and co-hosted by Huitong Financial and Nanshan Strategic Emerging Industry Investment, grandly opened in Shenzhen.As an annual industry event, this year's conference, themed "To the Future, Empowering New Beginnings," brought together over a thousand top investors, including Ni Zhengdong, Founder & Chairman of Zero2IPO Group and Chairman & CEO of Zero2IPO Holdings, and Jin Haitao, Chairman of Qianhai Ark Asset Management and Chief Executive Partner of Qia...

浏览次数：0

查看详情>>

发布时间: 2025 - 11 - 28

From Fancy to Future: Efung Capital's Zhu Pai Named to Pedata's 2025 "F40 China Young Investors"

Recently, Pedata, the entrepreneurship and investment information platform under Zero2IPO Holdings, officially announced its 2025 "F40 China Young Investors" list. Efung Capital CEO Zhu Pai was named to the list.The "F40 China Young Investors" selection has been held for eight consecutive years. The "F" stands for Fancy, representing boundless imagination, and also for Future, representing forward-looking vision. This list is dedicated to recognizing outstanding young investors under the age of 40 in China, uncovering the brave "catchers" behind unicorn ...

浏览次数：0

查看详情>>

发布时间: 2025 - 11 - 28

Monthly Health Read | November 2025

In November, Core Medical's STAR Market IPO application was accepted, making it the first innovative medical device company to be accepted since the resumption of the STAR Market's fifth-set listing standards. With this, Efung Capital has become the only institution since the resumption of the STAR Market's fifth-set standards to simultaneously have a presence spanning the first company to pass review and list (Orygen Biotech), the second company to pass review (Beixin Life), the first company to be accepted (Trinomab), and the first innovative medical device company to be accepted...

浏览次数：0

查看详情>>

发布时间: 2025 - 11 - 27

Xunlu Bio's Fucaso® Approved by Hong Kong for Relapsed/Refractory Multiple Myeloma

On November 27, 2025, Xunlu Bio announced that its independently developed fully human BCMA-targeted CAR-T cell therapy product Fucaso® (Equecabtagene Autoleucel) has received approval from the Hong Kong Department of Health for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have progressed after at least three prior lines of therapy.This marks Fucaso® as the first China-developed CAR-T cell therapy product approved in Hong Kong, and also the first domestically produced ATMP (Advanced Therapy Medicinal Product) to receive international PIC/S...

浏览次数：0

查看详情>>